Search
forLearn
5 / 801 resultslearn Fluocinolone
learn enoxolone
learn oleanolic acid
learn Gluconolactone
Research
5 / 1000+ results
research Alopecia Possibly Secondary to Topical Ophthalmic β-Blockers
Topical eye β-blockers may cause hair loss.
research Tumor Necrosis Factor in Sepsis
Topical eye β-blockers might cause hair loss, which usually gets better after stopping the medication.
research More Yellow Ovaries
Eye drops with β-blockers may cause hair loss.
research Drug Reactions Affecting Hair: Diagnosis
Some drugs can cause hair loss, change hair color and shape, or increase hair growth, and treatment may involve stopping the drug or using specific hair growth treatments.
research High resolution full scan liquid chromatography mass spectrometry comprehensive screening in sports antidoping urine analysis
The method effectively detects banned substances in urine for sports antidoping.
Community Join
5 / 1000+ resultscommunity Winlevi (clascoterone 1%) anyone trying it
Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.
community Winlevi just got FDA approval, projected to be available early 2021 in the US
The conversation is about creating a higher concentration of the newly FDA-approved hair loss treatment, Clascoterone (Winlevi), through compounding pharmacies and possibly organizing group purchases. Some users are unfamiliar with Winlevi and are asking for an explanation of the drug.
community Has anyone tried Winlevi (a.k.a. Clascoterone or CB-03-01) on their scalp yet?
The acne medication Winlevi, which contains Clascoterone, is available in the U.S. and may slow down hair loss until a higher concentration treatment, Breezula, is released.
community does anybody have winlevi clascoterone yet?
The conversation is about hair loss treatments, specifically discussing the use of Minoxidil, Finasteride, and RU58841. A user inquired about the availability of Winlevi (clascoterone) for hair loss.
community EMA is re-examining Winlevi (clascoterone at lower concentration)
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.